Erasca, Inc.Long
ERAS - long - breakout - upcoming catalysts
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
This is not a financial advice!
2 upcoming catalysts on 30rd of June and even more in 1Q and 2Q - 2024
Pretty high volume recently with Triangle breakout and pullback
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Keep an eye on 3.00, 3.30 and 4.50 levels, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 1.80
TP approx. 7.0
Most info on the chart.
Trade carefully!
This is not a financial advice!
2 upcoming catalysts on 30rd of June and even more in 1Q and 2Q - 2024
Pretty high volume recently with Triangle breakout and pullback
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Keep an eye on 3.00, 3.30 and 4.50 levels, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 1.80
TP approx. 7.0
Most info on the chart.
Trade carefully!
Join Discord channel:
whop.com/marketplace/contingent-traders/
contingenttrader.com/
whop.com/marketplace/contingent-traders/
contingenttrader.com/
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.